KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Research & Development (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Research & Development for 11 consecutive years, with $83.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 16.43% to $83.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $284.8 million through Dec 2025, down 8.2% year-over-year, with the annual reading at $284.8 million for FY2025, 8.2% down from the prior year.
  • Research & Development hit $83.5 million in Q4 2025 for CRISPR Therapeutics AG, up from $58.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $123.2 million in Q2 2022 to a low of $58.9 million in Q3 2025.
  • Historically, Research & Development has averaged $89.2 million across 5 years, with a median of $83.5 million in 2021.
  • Biggest five-year swings in Research & Development: surged 180.14% in 2021 and later decreased 28.31% in 2025.
  • Year by year, Research & Development stood at $103.1 million in 2021, then grew by 0.45% to $103.6 million in 2022, then dropped by 8.12% to $95.1 million in 2023, then decreased by 24.6% to $71.7 million in 2024, then increased by 16.43% to $83.5 million in 2025.
  • Business Quant data shows Research & Development for CRSP at $83.5 million in Q4 2025, $58.9 million in Q3 2025, and $69.9 million in Q2 2025.